$AC Immune (ACIU.US)$ AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M Benzinga· 10 mins ago5mins AC Immune (ACIU.US) 3.270 3.530 +2.83% +7.95% AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
$AC Immune (ACIU.US)$Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease Dow Jones· 7 mins ago AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
$AC Immune (ACIU.US)$ ac immune获得FDA快速通道设计,用于神经退行性诊断扫描 AC Immune的合作伙伴Life Molecular Imaging (LMI)已经因为Tau-PEt诊断[18F]PI-2620在三种神经退行性疾病(阿尔茨海默病,进行性核上性麻痹和皮质基底变性)中获得FDA的快速通道认定。正在进行III期临床开发的PI-2620,用于检测阿尔茨海默病中的Tau病理学,是一种下一代PEt成像剂...
AC Immune股票讨论
ac immune报告称,ACI-7104.056活性免疫疗法在早期帕金森病的2期试验中取得积极的中期结果
AC Immune报告了早期帕金森病中ACI-7104.056活性免疫疗法2期试验的积极中期结果
ac immune(纳斯达克:ACIU)宣布其ACI-7104.056进行中期研究的阶段2 VacSYn试验取得了积极的结果,这是一种用于早期帕金森病的活性免疫疗法。
该治疗显示出显著的疗效,在3次免疫接种后,诱导出的抗α同型卵白抗体水平比安慰剂高出16倍,患者反应率达100%。
试验报告展示了ac immune旗下ACI-7104.056的2期VacSYn试验取得了积极的中期效果。
AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
Benzinga· 10 mins ago5mins
AC Immune (ACIU.US)
3.270
3.530
+2.83%
+7.95%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
Dow Jones· 7 mins ago
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
ac immune收到第二个里程碑付款,因为ACI-35.030在早期阿尔茨海默病的20亿 ReTain临床试验取得进展
AC Immune SA(纳斯达克:ac immune)已收到Janssen Pharmaceuticals的第二笔2,460万瑞士法郎的里塞尔(ReTain)试验阶段20亿中ACI-35.030(JNJ-2056)用于临床前阿尔茨海默病的快速预筛率。这使得该试验的总里程碑付款达到2500万瑞士法郎。可能的注册...
ac immune获得FDA快速通道设计,用于神经退行性诊断扫描
AC Immune的合作伙伴Life Molecular Imaging (LMI)已经因为Tau-PEt诊断[18F]PI-2620在三种神经退行性疾病(阿尔茨海默病,进行性核上性麻痹和皮质基底变性)中获得FDA的快速通道认定。正在进行III期临床开发的PI-2620,用于检测阿尔茨海默病中的Tau病理学,是一种下一代PEt成像剂...
AC Immune在AAIC 2024展示其用于治疗神经退行性疾病的新型形构器-抗体药物偶联物(morphomer-Antibody Drug Conjugate)平台
AC Immune SA(NASDAQ: ACIU)将在费城举行的阿尔茨海默病协会国际会议(AAIC 2024)上,展示其用于神经退行性疾病的精准医学研究管线。展示将侧重于:
1. [18F]ACI-19626是一种首创的TDP-43-PEt示踪剂
2. ACI-24.060是一种...
暂无评论